Fulminant liver failure is an uncommon but life-threatening complication of severe dengue infection. Molecular adsorbent recirculating system (MARS), which reverses hepatic encephalopathy, is an emerging important element in the armamentarium of organ support in the intensive care unit in patients suffering from acute liver failure. We report an intensive care unit case of fulminant liver failure secondary to dengue hemorrhagic fever, which was supported with MARS. MARS led to rapid reversal of biochemical profile and encephalopathy, resulting in early extubation and intensive care unit discharge.
Sam K, Ib G, Prv K.Epidemiology, clinical features, laboratory investigations and early diagnosis of dengue fever in adults: a descriptive study in Sri Lanka. Southeast Asian J Trop Med Public Health. 2005;36: 686-692.
2.
Innis BL, Myint KSA, Nisalak A, et al.Acute liver failure is one important cause of fatal dengue infection. Southeast Asian J Trop Med Public Health. 1990;21: 695-696.
3.
Bethell DB, Flobbe K, Phuong CX, et al.Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis. 1998;177: 778-782.
4.
Rosen L, Khin MM.Recovery of virus from the liver of children with fatal dengue: reflection on the pathogenesis of the disease and its possible analogy with that of yellow fever. Res Virol. 1989;140: 351-360.
5.
Marianneau P, Cardona A, Edelman L, et al.Dengue virus replication in human hepatoma cells activates NF-kB which in turn induces apoptotic cell death. J Virol. 1997;71: 3244-3249.
6.
Shakil AO, Kramen D, Mazariegos GV, et al.Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000;6: 163-169.
7.
Barshes N, Gay AN, Williams B, et al.Support for the acutely failing liver: a comprehensive review of historic and contemporary strategy. J Am Coll Surg. 2005;201: 458-476.
8.
Larsen FS, Hansen BA, Blei AT, et al.Intensive care management of patients with acute liver failure with emphasis on systemic hemodynamic instability and cerebral edema: a critical appraisal of pathophysiology. Can J Gastroenterol. 2000;14: 105-111.
9.
Pless G, Sauer IM.Bioartificial liver: current status. Transplant Proc. 2005;37: 3893-3895.
10.
Tan HK.Molecular adsorbent recirculating system (MARS). Ann Acad Med Singapore. 2004;33: 329-335.
11.
Mitzner SR, Stange J, Klammt S, et al.Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol. 2001;12: S75-S82.
12.
Di Campli C, Zocco MA, Gaspari R, et al.The decrease in cytokine concentration during albumin dialysis correlates with the prognosis of patients with acute on chronic liver failure. Transpl Proc. 2005;37: 2551-2553.
13.
Kjaergard L, Liu J, Als-Nielsen B, et al.Artificial and bioartificial support systems for acute and acute-on-chronic liver failure. JAMA. 2003;289: 217-222.
14.
Mitzner SR, Strange J, Klammt S, et al.Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: result of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000;6: 277-286.
15.
Heemann U, Treichel U, Loock J, et al.Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective controlled study. Hepatol. 2002;36: 949-958.
16.
Koivusalo AM, Vakkuri A, Hockerstedt K, et al.Experience of MARS therapy with and without transplantation in 101 patients with liver insufficiency. Transplant Proc. 2005;37: 3315-3317.
17.
Steiner C, Zinggrebe A, Vertler A.Experiences with MARS therapy in liver disease: analysis of 385 patients of the International MARS Registry. Hepatology. 2003;38: 239A-239A.
